Voyager Therapeutics Announces Appointment of Toby Ferguson as Chief Medical Officer
13 mars 2024 07h00 HE
|
Voyager Therapeutics, Inc.
LEXINGTON, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced the appointment...
Voyager Therapeutics Reports Fourth Quarter and Full Year 2023 Financial and Operating Results
28 févr. 2024 16h01 HE
|
Voyager Therapeutics, Inc.
- Company had approximately $431 million in pro-forma cash as of December 31, 2023, adjusted for $100 million consideration from Novartis agreements and $100 million public offering - - Strong cash...
Voyager Therapeutics Announces Selection of Gene Therapy Development Candidate for Friedreich’s Ataxia in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment
26 févr. 2024 07h00 HE
|
Voyager Therapeutics, Inc.
LEXINGTON, Mass., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that the joint...
Voyager Therapeutics Announces Fourth Quarter 2023 Conference Call and Webcast
21 févr. 2024 07h00 HE
|
Voyager Therapeutics, Inc.
LEXINGTON, Mass., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced it will report...
Voyager Therapeutics Reports Robust Preclinical Activity in Tau Silencing Gene Therapy Program for Alzheimer’s Disease and Advances Program into Late Research
20 févr. 2024 07h00 HE
|
Voyager Therapeutics, Inc.
- Additional new data demonstrate VY-TAU01, Voyager’s lead antibody targeting pathological tau, was well-tolerated and demonstrated favorable pharmacokinetics in non-human primates (NHPs) - - Data to...
Voyager Therapeutics to Present at the Oppenheimer Annual Life Sciences Conference
07 févr. 2024 07h00 HE
|
Voyager Therapeutics, Inc.
LEXINGTON, Mass., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that Chief...
Voyager Therapeutics Announces Pricing of Public Offering
04 janv. 2024 22h45 HE
|
Voyager Therapeutics, Inc.
LEXINGTON, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced the pricing of...
Voyager Therapeutics Announces Proposed Public Offering
04 janv. 2024 16h14 HE
|
Voyager Therapeutics, Inc.
LEXINGTON, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that it has...
Voyager Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
03 janv. 2024 07h00 HE
|
Voyager Therapeutics, Inc.
LEXINGTON, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that Chief...
Voyager Therapeutics Enters Capsid License Agreement and Strategic Collaboration with Novartis to Advance Novel Gene Therapies
02 janv. 2024 07h00 HE
|
Voyager Therapeutics, Inc.
- Collaboration with gene therapy leader Novartis aims to discover and develop new approaches for Huntington’s disease and spinal muscular atrophy - - Voyager to receive up-front consideration of...